Investing

Mineralys Therapeutics : MLYS

MLYS

Stock Data

$29.26

$2.61 (9.79%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Mineralys Therapeutics, based in Radnor, Pennsylvania, is a biopharmaceutical company focused on creating treatments for hypertension and related cardiovascular conditions. Founded in 2019, it's at the forefront with its leading product, lorundrostat, an innovative oral medication designed to selectively inhibit aldosterone synthase, aiming to help patients with hypertension that's difficult to control with existing therapies.

All Mineralys Therapeutics Articles

3 Articles

Trey Thoelcke | Oct 17, 2025 at 8:45 AM EDT

Insiders Bet Big on These 3 Fintech and Biotech Stocks

In the past week or so, a fintech firm and two biotechs saw some huge insider buying. However, these were…

Trey Thoelcke | Oct 7, 2025 at 8:45 AM EDT

Insiders Snap Up $54M in Biotech and Offshore Driller Stocks

In the past week or so, some public offerings prompted huge insider buying. However, these were not the only notable…

Trey Thoelcke | May 1, 2025 at 8:45 AM EDT

Carl Icahn Buys More Shares, and Tesla Insider Bucks the Selling Trend

Though insider buying has slowed during the first-quarter earnings reporting season, some insiders continued to build stakes or bucked selling…